Genome Canada Notes to the financial statements March 31, 2017 (in thousands of dollars) Page 8 7. Deferred contributions related to capital assets Deferred contributions related to capital assets represent restricted contributions with which capital assets were originally purchased. The changes in the deferred contributions balance for the year are as follows: 2017 2016 $ $ Balance, beginning of year 118 159 Add: acquisition of capital assets 35 9 Less: amounts amortized to revenue (53) (50) Balance, end of year 100 118 8. Supplemental cash flow information 2017 2016 $ $ Gain (loss) on disposal of investments (81) 42 Amount transferred to capital assets (35) (9) Fair value adjustment (61) (81) (177) (48) 9. Commitments Committed funding The Corporation is committed to finance approved research projects, science and technology platforms and Genome Centre operations in accordance with established agreements. As at March 31, 2017, the payments committed are approximately $47,987 in 2018 and $60,942 for other future years. Operating leases The Corporation leases its premises and equipment under long-term operating leases, which expire at various dates between 2018 and 2021. The minimum aggregate lease payments are approximately as follows: $ 2018 154 2019 34 2020 9 2021 4